Date: 2015-01-30
Type of information: Licensing agreement
Compound: Factor VIIa for pulmonary administration
Company: CMC Biologics (Denmark - USA) Serendex Pharmaceuticals (Denmark)
Therapeutic area: Cardiovascular diseases - Lung diseases - Hematological diseases
Type agreement: licensing development
Action mechanism: protein/coagulation factor. I
Disease: diffuse alveolar hemorrhage
Details: * On January 30, 2015, Serendex Pharmaceuticals and CMC Biologics have signed an exclusive agreement on Factor VIIa. Through the agreement, Serendex Pharmaceuticals has secured access to a unique form of Factor VIIa and the agreement provides Serendex Pharmaceuticals with exclusive rights for the development and commercialization of Factor VIIa for pulmonary administration. The therapeutic focus will be on acute bleeding in the lungs (Diffuse Alveolar Hemorrhage) and if successful Serendex Pharmaceuticals might be able to offer breakthrough therapy in this indication. CMC Biologics, which provides bioprocessing solutions to pharmaceutical and biotechnology companies, will develop, manufacture and supply Factor VIIa bulk drug substance for acute pulmonary administration for pre?clinical and clinical studies as well as for commercialization on behalf of Serendex Pharmaceuticals. The contract is a great leap forward for Serendex Pharmaceuticals, which could lead to a market approval for FVIIa within five years.
Financial terms:
Latest news:
